Loading...
XSHE
300147
Market cap874mUSD
Dec 05, Last price  
9.38CNY
1D
0.64%
1Q
-16.55%
Jan 2017
-26.23%
IPO
-47.65%
Name

Xiangxue Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHE:300147 chart
P/E
P/S
3.33
EPS
Div Yield, %
Shrs. gr., 5y
0.24%
Rev. gr., 5y
-7.78%
Revenues
1.86b
-19.16%
258,307,517294,808,980378,633,317513,383,583616,090,220801,020,2121,261,114,6511,523,980,1381,464,604,8421,862,087,8732,187,317,4382,504,252,3472,786,199,5163,072,090,6552,970,575,8412,187,069,9012,299,287,6821,858,662,132
Net income
-859m
L+120.73%
30,780,82935,950,73050,916,52874,199,46883,496,930107,167,519158,242,572196,796,127177,297,88466,024,14465,939,17856,439,310126,129,566141,797,31600-388,963,842-858,559,973
CFO
18m
-93.10%
138,016,02155,723,41746,186,86345,465,55829,553,113118,907,426328,367,622165,580,270159,890,412198,481,275109,533,18491,238,23583,019,533257,180,838257,562,269227,377,262263,441,90218,174,822
Dividend
Jun 23, 20200.046 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Xiangxue Pharmaceutical Co., Ltd. engages in the research and development, procurement, manufacture, delivery, and distribution of pharmaceutical products in China. It offers antivirotic oral liquids under the Xiangxue brand name; and healthcare supplements, as well as health solutions, such as food and beverage. Xiangxue Pharmaceutical Co., Ltd. has strategic partnership agreement with 111, Inc. to develop the Internet + Medicine model for China's traditional Chinese medicine industry. The company was founded in 1997 and is based in Guangzhou, China.
IPO date
Dec 15, 2010
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT